262 related articles for article (PubMed ID: 31701458)
1. Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy.
Siwy J; Ahonen L; Magalhães P; Frantzi M; Rossing P
Methods Mol Biol; 2020; 2067():287-306. PubMed ID: 31701458
[TBL] [Abstract][Full Text] [Related]
2. Proteomics and Metabolomics in Kidney Disease, including Insights into Etiology, Treatment, and Prevention.
Dubin RF; Rhee EP
Clin J Am Soc Nephrol; 2020 Mar; 15(3):404-411. PubMed ID: 31636087
[TBL] [Abstract][Full Text] [Related]
3. The role of urinary peptidomics in kidney disease research.
Klein J; Bascands JL; Mischak H; Schanstra JP
Kidney Int; 2016 Mar; 89(3):539-45. PubMed ID: 26880450
[TBL] [Abstract][Full Text] [Related]
4. Insights into predicting diabetic nephropathy using urinary biomarkers.
Khan NU; Lin J; Liu X; Li H; Lu W; Zhong Z; Zhang H; Waqas M; Shen L
Biochim Biophys Acta Proteins Proteom; 2020 Oct; 1868(10):140475. PubMed ID: 32574766
[TBL] [Abstract][Full Text] [Related]
5. Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics.
Ibarra-González I; Cruz-Bautista I; Bello-Chavolla OY; Vela-Amieva M; Pallares-Méndez R; Ruiz de Santiago Y Nevarez D; Salas-Tapia MF; Rosas-Flota X; González-Acevedo M; Palacios-Peñaloza A; Morales-Esponda M; Aguilar-Salinas CA; Del Bosque-Plata L
Acta Diabetol; 2018 Nov; 55(11):1151-1161. PubMed ID: 30173364
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive metabolic biomarkers for early diagnosis of diabetic nephropathy: Meta-analysis of profiling metabolomics studies.
Roointan A; Gheisari Y; Hudkins KL; Gholaminejad A
Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2253-2272. PubMed ID: 34059383
[TBL] [Abstract][Full Text] [Related]
7. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Siwy J; Schanstra JP; Argiles A; Bakker SJ; Beige J; Boucek P; Brand K; Delles C; Duranton F; Fernandez-Fernandez B; Jankowski ML; Al Khatib M; Kunt T; Lajer M; Lichtinghagen R; Lindhardt M; Maahs DM; Mischak H; Mullen W; Navis G; Noutsou M; Ortiz A; Persson F; Petrie JR; Roob JM; Rossing P; Ruggenenti P; Rychlik I; Serra AL; Snell-Bergeon J; Spasovski G; Stojceva-Taneva O; Trillini M; von der Leyen H; Winklhofer-Roob BM; Zürbig P; Jankowski J
Nephrol Dial Transplant; 2014 Aug; 29(8):1563-70. PubMed ID: 24589724
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy.
Hirayama A; Nakashima E; Sugimoto M; Akiyama S; Sato W; Maruyama S; Matsuo S; Tomita M; Yuzawa Y; Soga T
Anal Bioanal Chem; 2012 Dec; 404(10):3101-9. PubMed ID: 23052862
[TBL] [Abstract][Full Text] [Related]
9. Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics.
Van JA; Scholey JW; Konvalinka A
J Am Soc Nephrol; 2017 Apr; 28(4):1050-1061. PubMed ID: 28159781
[TBL] [Abstract][Full Text] [Related]
10. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy.
Alkhalaf A; Zürbig P; Bakker SJ; Bilo HJ; Cerna M; Fischer C; Fuchs S; Janssen B; Medek K; Mischak H; Roob JM; Rossing K; Rossing P; Rychlík I; Sourij H; Tiran B; Winklhofer-Roob BM; Navis GJ;
PLoS One; 2010 Oct; 5(10):e13421. PubMed ID: 20975990
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics of the diabetic nephropathy: behind the fingerprint of development and progression indicators.
Cordero-Pérez P; Sánchez-Martínez C; García-Hernández PA; Saucedo AL
Nefrologia (Engl Ed); 2020; 40(6):585-596. PubMed ID: 33036786
[TBL] [Abstract][Full Text] [Related]
12. Changes in urine proteome accompanying diabetic nephropathy progression.
Lewandowicz A; Bakun M; Kohutnicki R; Fabijańska A; Kistowski M; Imiela J; Dadlez M
Pol Arch Med Wewn; 2015; 125(1-2):27-38. PubMed ID: 25578432
[TBL] [Abstract][Full Text] [Related]
13. Body fluid peptide and protein signatures in diabetic kidney diseases.
Jankowski J; Schanstra JP; Mischak H
Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv43-53. PubMed ID: 26209737
[TBL] [Abstract][Full Text] [Related]
14. Applying proteomics to diagnosis of diabetic kidney disease.
Moresco RN; De Carvalho JAM
Expert Rev Proteomics; 2017 Oct; 14(10):841-843. PubMed ID: 28893107
[No Abstract] [Full Text] [Related]
15. Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy.
Fugmann T; Borgia B; Révész C; Godó M; Forsblom C; Hamar P; Holthöfer H; Neri D; Roesli C
Kidney Int; 2011 Aug; 80(3):272-81. PubMed ID: 21544065
[TBL] [Abstract][Full Text] [Related]
16. Identification of nephropathy predictors in urine from children with a recent diagnosis of type 1 diabetes.
Magagnotti C; Zerbini G; Fermo I; Carletti RM; Bonfanti R; Vallone F; Andolfo A
J Proteomics; 2019 Feb; 193():205-216. PubMed ID: 30366120
[TBL] [Abstract][Full Text] [Related]
17. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients.
Dihazi H; Müller GA; Lindner S; Meyer M; Asif AR; Oellerich M; Strutz F
Clin Chem; 2007 Sep; 53(9):1636-45. PubMed ID: 17634209
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy: traditional to proteomic markers.
Moresco RN; Sangoi MB; De Carvalho JA; Tatsch E; Bochi GV
Clin Chim Acta; 2013 Jun; 421():17-30. PubMed ID: 23485645
[TBL] [Abstract][Full Text] [Related]
19. Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease.
Jiang X; Liu X; Qu X; Zhu P; Wo F; Xu X; Jin J; He Q; Wu J
Theranostics; 2023; 13(10):3188-3203. PubMed ID: 37351171
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
